中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Influence of different virologic responses on the prognosis of patients with decompensated hepatitis B cirrhosis

DOI: 10.3969/j.issn.1001-5256.2020.05.017
Research funding:

 

  • Received Date: 2019-12-16
  • Published Date: 2020-05-20
  • Objective To investigate the influence of different virologic responses on long-term survival rate and incidence rate of liver cancer in patients with decompensated hepatitis B cirrhosis.Methods A total of 378 patients with decompensated hepatitis B cirrhosis who were admitted to The Affiliated Hospital of Xuzhou Medical University from September 2010 to September 2016 were enrolled, and according to whether HBV DNA was continuously undetectable during antiviral therapy, they were divided into sustained virologic response group with 243 patients and non-sustained virologic response group with 135 patients. The patients were stratified according to the application of different antiviral drugs. Baseline data were recorded and the patients were followed up to the occurrence of end events or study endpoint to record death and hepatocellular carcinoma(HCC). The independent samplest-test was used for comparison of normally distributed continuous data between two groups, and the Mann-WhitneyUtest was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between groups. The Kaplan-Meier method was used to plot survival curves, and the log-rank test was used to compare survival rates between groups.Results Compared with the non-sustained virologic response group, the sustained virologic response group had a significantly lower 5-year cumulative incidence rate of HCC(7.4% vs19.3%,χ2 =10.627,P= 0. 001) and a significantly higher 5-year transplant-free survival rate(93. 4% vs 80. 7%,χ2 =12.594,P<0.001). For the sustained virologic response group, there were no significant differences between the entecavir group and the non-entecavir group in the 5-year transplant-free survival rate(94.7% vs 90.2%,χ2 =1.122,P= 0. 290) and the 5-year cumulative incidence rate of liver cancer(6.4 % vs 9.7%,χ2 =0.552,P= 0. 458). For the non-sustained viral response group, there were also no significant differences between the entecavir group and the non-entecavir group in the 5-year transplant-free survival rate(78. 4% vs 82. 8%,χ2 =1.526,P= 0. 217) and the 5-year cumulative incidence rate of liver cancer(21. 5% vs 17. 1%,χ2 =1.844,P= 0. 174).Conclusion Antiviral therapy can improve the prognosis of patients with decompensated hepatitis B cirrhosis, and sustained virologic response can reduce the incidence rate of liver cancer and prolong survival time.

     

  • [1] FATTOVICH G, GIUSTINA G, SCHALM SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B virus and cirrhosis[J]. Hepatology, 1995, 21(1):77-82.
    [2] PENG CY, CHIEN RN, LIAW YF. Hepatitis B virus-related decompensated liver cirrhosis:Benefits of antiviral therapy[J]. J Hepatol, 2012, 57(2):442-450.
    [3] SINGAL AK, FONTANA RJ. Meta-analysis:Oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis[J]. Aliment Pharmacol Ther, 2012, 35(6):674-689.
    [4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol, 2015, 31(12):1941-1960.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015, 31(12):1941-1960.
    [5] FATTOVICH G, BORTOLOTTI F, DONATO F. Natural history of chronic hepatitis B:Special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48(2):335-352.
    [6] JANG JW, CHOI JY, KIM YS, et al. Effects of virologic response to treatment on short-and long-term outcomes of patients with chronic hepatitis B virus infection and decompensated cirrhosis[J]. Clin Gastroenterol Hepatol, 2018, 16(12):1954-1963. e3.
    [7] FONTANA RJ, HANN HW, PERRILLO RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy[J]. Gastroenterology,2002, 123(3):719-727.
    [8] CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1):65-73.
    [9] JU YC, JUN DW, CHOI J, et al. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis[J]. World J Gastroenterol, 2018, 24(40):4606-4614.
    [10] KIM TS, SINN DH, KANG W, et al. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia[J]. J Gastroenterol Hepatol, 2019, 34(11):2028-2035.
    [11] PAPATHEODORIDIS GV, MANOLAKOPOULOS S, TOULOUMI G,et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s)starting with lamivudine monotherapy:Results of the nationwide HEPNET.Greece cohort study[J]. Gut, 2011, 60(8):1109-1116.
    [12] HOSAKA T, SUZUKI F, KOBAYASHI M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection[J]. Hepatology, 2013, 58(1):98-107.
    [13] PAPATHEODORIDIS GV, MANOLAKOPOULOS S, TOULOUMI G, et al. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir:HepNet. Greece cohort[J]. J Viral Hepat, 2015,22(2):120-127.
    [14] HOU JL, ZHAO W, LEE C, et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries[J]. Clin Gastroenterol Hepatol, 2020, 18(2):457-467. e21.
    [15] NAM JY, CHANG Y, CHO H, et al. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B[J]. J Viral Hepat, 2018, 25(5):552-560.
  • Cited by

    Periodical cited type(13)

    1. 张娟,蔡大川. 核苷(酸)类似物药物浓度监测在慢性乙型肝炎抗病毒治疗中的研究进展. 中华传染病杂志. 2023(02): 167-170 .
    2. 王军,孙妍妍. 持续病毒学应答对失代偿期乙型病毒性肝炎肝硬化患者预后的影响. 中国卫生工程学. 2023(03): 418-420 .
    3. 廖洪柳,徐海锋,徐维蔓. 乙型肝炎肝硬化患者HBV-DNA载量与α-SMA、AFP及肝纤维化的关系. 中南医学科学杂志. 2023(06): 966-969 .
    4. 王明杰. 富马酸丙酚替诺福韦治疗慢性乙型肝炎的研究进展. 现代诊断与治疗. 2022(05): 668-670 .
    5. 杨鑫,刘小静,王丽,李洁洁,张佳丽,武珊珊. 低血糖对老年失代偿期肝硬化住院患者短期预后的影响. 老年医学与保健. 2022(03): 627-631 .
    6. 张惠敏,任明珠,滕艳秋. 不同护理策略在乙型肝炎肝硬化失代偿期患者中的应用效果. 中西医结合护理(中英文). 2022(01): 154-156 .
    7. 阮佳佳,温世飞,王霞,李丽,傅涓涓,潘修成. 首次失代偿期乙型肝炎肝硬化患者获得再代偿的影响因素分析. 临床肝胆病杂志. 2022(08): 1796-1800 . 本站查看
    8. 各廷秋,钟艳丹,俞海英,丁巧云,郭银燕,曹兴国,彭姗姗. 分析不同核苷(酸)类似物初始治疗乙型肝炎肝硬化的临床效果. 世界复合医学. 2022(10): 139-142 .
    9. 陈丽文,祝达,谢竟全,张倩华,高文军. 三种抗病毒治疗方案对ETV经治低病毒血症CHB患者HBV DNA转阴时间差异分析. 海南医学. 2021(06): 689-691 .
    10. 王文珊. 恩替卡韦治疗失代偿期乙型肝炎肝硬化的疗效及对肝纤维化的影响. 现代养生. 2021(12): 36-38 .
    11. 胡璇,李彤,王玉珊,麻爱娣,刘元元,张岭漪. 丙酚替诺福韦治疗慢性乙型肝炎的临床研究进展. 胃肠病学和肝病学杂志. 2021(08): 950-954 .
    12. 王晓莹. 恩替卡韦联合长效干扰素α2b治疗乙型病毒性肝炎后肝硬化的临床疗效及其对肝功能和肝纤维化指标的影响. 临床合理用药杂志. 2021(33): 98-101 .
    13. 薛兴伟. 肝炎后肝硬化患者血清TBA、GGT、ALB、CHE、CHO检验价值. 中国医药指南. 2020(36): 97-98 .

    Other cited types(1)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (911) PDF downloads(138) Cited by(14)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return